Uniqure N.V. recently released its financial results for the fourth quarter and full year of 2025. The company reported having approximately $622.5 million in cash, cash equivalents, and current investment securities as of December 31, 2025, which is a significant increase from the $367.5 million it held at the end of 2024.
In terms of revenues, the company reported $16.1 million for the year ended December 31, 2025, a decrease from the $27.1 million reported in 2024. This decrease was primarily driven by a $10.7 million decrease in collaboration revenue and a $6.1 million decrease in contract manufacturing revenues.
The cost of contract manufacturing revenues was nil for the year ended December 31, 2025, compared to $17.1 million in 2024, following the divestment of the Lexington facility in 2024.
Research and development expenses were $140.7 million for the year ended December 31, 2025, slightly lower than the $143.8 million reported in 2024. The decrease was primarily driven by a $26.0 million decrease in total other research and development expenses.
Selling, general, and administrative expenses were $65.5 million for the year ended December 31, 2025, compared to $52.7 million in 2024. The increase was primarily driven by a $9.4 million increase in professional fees and a $3.6 million increase in employee and contractor-related expenses.
The net loss for the year ending December 31, 2025, was $199.0 million, or $3.46 basic and diluted loss per ordinary share, compared to a $239.6 million net loss for the same period in 2024, or $4.92 basic and diluted loss per ordinary share.
The company's cash position, revenues, expenses, and net loss all reflect significant changes compared to the previous period, demonstrating the company's financial performance and position in the market. The market has reacted to these announcements by moving the company's shares 3.91% to a price of $22.84. For more information, read the company's full 8-K submission here.
